Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 15 results for memantine

  1. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

  2. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

  3. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

  4. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: TBC

  5. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: 30 April 2025

  6. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

  7. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  8. Past appeals and decisions

    TA111 Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review) 13-14 August 2006 TA142 Anaemia...

  9. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    Comes from guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Number TA217

  10. Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

    Comes from guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Number TA217

  11. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

  12. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  13. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

  14. Research recommendations

    effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if...